公开(公告)号：US20160151482A1

公开(公告)日：2016-06-02

申请号：US14781765

申请日：2014-04-02

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： Eric C. Carnes ,  C. Jeffrey Brinker ,  Carlee Erin Ashley

IPC: A61K39/39 ,  A61K9/14 ,  A61K9/51

CPC classification number: A61K39/39 ,  A61K9/127 ,  A61K9/146 ,  A61K9/5115 ,  A61K9/5184 ,  A61K31/365 ,  A61K38/19 ,  A61K39/0208 ,  A61K39/07 ,  A61K39/08 ,  A61K45/06 ,  A61K47/6923 ,  A61K47/6929 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2300/00

Abstract: The present invention relates to mesoporous alum nanoparticles which can be used as a universal platform for antigen adsorption, presentation and delivery to provide immune compositions, including vaccines and to generate an immune response (preferably, both humoral and cell mediated immune response), preferably a heightened immune response to the presentation of one or more antigens to a patient or subject.

Abstract translation: 本发明涉及介孔矾纳米颗粒，其可用作抗原吸附，呈递和递送的通用平台，以提供免疫组合物，包括疫苗和产生免疫应答（优选体液和细胞介导的免疫应答），优选为 增加对一种或多种抗原呈递给患者或受试者的免疫应答。

公开(公告)号：US20170165375A1

公开(公告)日：2017-06-15

申请号：US14781817

申请日：2014-04-02

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： Carlee Erin Ashley ,  Eric C. Carnes ,  Terry Wu ,  Linda A. Felton ,  Darryl Y. Sasaki

IPC: A61K9/51 ,  A61K9/50 ,  A61K31/5383 ,  A61K31/65 ,  A61K31/546 ,  A61K31/635 ,  A61K31/505 ,  A61K9/00 ,  A61K9/127 ,  A61K31/7036

CPC classification number: A61K31/7036 ,  A61K9/0053 ,  A61K9/1271 ,  A61K9/1274 ,  A61K9/5021 ,  A61K9/5123 ,  A61K31/505 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/635 ,  A61K31/65 ,  A61K47/52 ,  A61K47/60 ,  A61K47/62 ,  A61K47/68 ,  A61K47/6913 ,  A61K47/6917 ,  A61K47/6923 ,  A61K47/6929 ,  B82Y5/00 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481

Abstract: The invention provides novel antibiotic protocells comprising mesoporous nanoparticles encapsulated within a lipid bi- or multilayer. The nanoparticles have pore sizes and surface chemistries that enable facile adsorption and intracellular presentation of antibiotics which are effective in the treatment of a wide variety of bacterial infections, including F. tularensis, B. pseudomallei and P. aeruginosa-related infections. Related pharmaceutical compositions and methods of treatment are also provided.

公开(公告)号：US20150010475A1

公开(公告)日：2015-01-08

申请号：US14369741

申请日：2012-12-31

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  David S. Peabody ,  Walker Kip Wharton ,  Bryce Chackerian ,  Carlee Erin Ashley ,  Cheryl L. Willman ,  Eric C. Carnes ,  Katherine Epler ,  Robert Eric Castillo

IPC: A61K47/48 ,  C12N15/113 ,  C12N15/11 ,  C07K7/06 ,  A61K31/704

CPC classification number: A61K31/704 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6911 ,  C07K7/06 ,  C12N15/111 ,  C12N15/113

Abstract: The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.

Abstract translation: 本发明涉及其用途，其可用于将可用于递送药物载体的CRLF-2和CD19结合肽进一步修饰的磷脂生物层结合到表达CRLF-2和CD19的细胞中，从而治疗癌症 特别是急性淋巴细胞白血病（ALL），包括（B-前体急性成淋巴细胞白血病（B-ALL）），用于治疗癌症的新型CRLF-2结合肽和CLRF-2和CD19结合病毒样颗粒（VLP） ，也包括ALL。

公开(公告)号：US20180105430A1

公开(公告)日：2018-04-19

申请号：US15557368

申请日：2016-03-11

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： Eric C. Carnes ,  C. jeffrey Brinker ,  Darren Dunphy ,  Trevin Heisey

IPC: C01B33/18

CPC classification number: C01B33/18 ,  A61K9/5115 ,  A61K9/5123 ,  A61K33/00 ,  B82Y40/00 ,  C01B37/02 ,  C01P2004/64 ,  C01P2006/14 ,  C01P2006/17

Abstract: The present invention relates to the discovery that mesoporous silica nanoparticles may be modified in pore size from the natural mesophase by generating mesoporous materials in binary, ternary or multiphase surfactant systems to produce biphasic, triphasic or multiphase mesoporous structures. Thus, the present invention relates to methods of producing biphase, triphasic and multiphase mesoporous structures with finely tuned mesopore size and protocells which are produced therefrom and mesoporous silica nanoparticles obtained therefrom. The resulting mesoporous nanostructures may be used to create protocells having unique cargo loading and release characteristics. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

公开(公告)号：US20170232115A1

公开(公告)日：2017-08-17

申请号：US15380962

申请日：2016-12-15

Applicant: STC.UNM ,  Sandia Corporation

Inventor： Carlee Erin Ashley ,  C. Jeffrey Brinker ,  Eric C. Carnes ,  Mohammed Houman Fekrazad ,  Linda A. Felton ,  Oscar Negrete ,  David Patrick Padilla ,  Brian S. Wilkinson ,  Dan C. Wilkinson ,  Cheryl L. Willman

IPC: A61K49/00 ,  A61K33/24 ,  A61K31/513 ,  C12N15/113 ,  A61K38/45 ,  A61K31/506 ,  A61K38/47 ,  A61K31/465 ,  A61K31/192 ,  A61K31/704 ,  A61K48/00

CPC classification number: A61K48/0008 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/1271 ,  A61K9/5078 ,  A61K31/192 ,  A61K31/465 ,  A61K31/506 ,  A61K31/513 ,  A61K31/704 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K33/24 ,  A61K38/00 ,  A61K38/17 ,  A61K38/45 ,  A61K38/47 ,  A61K45/06 ,  A61K47/6923 ,  A61K49/0082 ,  A61K49/0423 ,  B82Y5/00 ,  C07K7/06 ,  C07K2319/00 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2810/40 ,  C12Y204/02036 ,  C12Y302/02022 ,  A61K2300/00

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

公开(公告)号：US10022327B2

公开(公告)日：2018-07-17

申请号：US14970998

申请日：2015-12-16

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Eric C. Carnes ,  Carlee Erin Ashley ,  Cheryl L. Willman

IPC: A61K9/127 ,  A61K31/704 ,  A61K31/711 ,  A61K33/24 ,  A61K39/05 ,  C12N15/113 ,  C07K14/47 ,  C12N15/88 ,  A61K45/06 ,  A61K47/62 ,  A61K47/69 ,  A61K38/00 ,  A61K48/00

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

公开(公告)号：US20190091150A1

公开(公告)日：2019-03-28

申请号：US16025557

申请日：2018-07-02

Applicant: STC.UNM ,  Sandia Corporation

Inventor： C. Jeffrey Brinker ,  Eric C. Carnes ,  Carlee Erin Ashley ,  Cheryl L. Willman

IPC: A61K9/127 ,  A61K31/704 ,  A61K33/24 ,  A61K47/69 ,  C07K14/47 ,  A61K45/06 ,  A61K47/62 ,  C12N15/88 ,  A61K39/05 ,  C12N15/113 ,  A61K31/711 ,  A61K48/00 ,  A61K38/00

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

公开(公告)号：US20160106671A1

公开(公告)日：2016-04-21

申请号：US14970998

申请日：2015-12-16

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Eric C. Carnes ,  Carlee Erin Ashley ,  Cheryl L. Willman

IPC: A61K9/127 ,  C12N15/113 ,  A61K39/05 ,  A61K31/711 ,  A61K31/704 ,  A61K33/24

CPC classification number: A61K9/1271 ,  A61K31/704 ,  A61K31/711 ,  A61K33/24 ,  A61K38/00 ,  A61K39/05 ,  A61K45/06 ,  A61K47/62 ,  A61K47/6901 ,  A61K48/0016 ,  C07K14/47 ,  C12N15/1135 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2810/40

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

Abstract translation: 本发明涉及用于特异性靶向肝细胞和其它癌细胞的原细胞，其包含具有支持的脂质双层的纳米多孔二氧化硅核心; 至少一种促进癌细胞死亡的药物（例如传统的小分子，大分子货物（例如siRNA或蛋白质毒素如蓖麻毒素A链或白喉毒素A链）和/或组蛋白包装的质粒DNA 设置在纳米多孔硅芯内（优选超螺旋以更有效地将DNA包装到原细胞中），其任选地用核定位序列修饰以帮助定位癌细胞核内的原细胞，以及表达参与治疗的肽的能力 （凋亡/细胞死亡）或作为报告物，靶向肽靶向待治疗的组织中的癌细胞，使得原细胞与靶细胞的结合是特异性和增强的，并且促进内体逃逸的融合肽 原细胞和包封的DNA。根据本发明的原细胞可用于治疗癌症，特别是包括肝细胞（肝）癌症 选择性结合肝细胞组织或在癌症诊断中起作用的新型结合肽（c-MET肽），包括癌症治疗和药物发现。

公开(公告)号：US20150272885A1

公开(公告)日：2015-10-01

申请号：US14350674

申请日：2012-10-12

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： Carlee Erin Ashley ,  C. Jeffrey Brinker ,  Eric C. Carnes ,  Mohammad Houman Fekrazad ,  Linda A. Felton ,  Oscar Negrete ,  David Patrick Padilla ,  Brian S. Wilkinson ,  Dan C. Wilkinson ,  Cheryl L. Willman

IPC: A61K9/127 ,  A61K45/06 ,  A61K31/704 ,  A61K31/513 ,  A61K31/713 ,  A61K38/17

CPC classification number: A61K48/0008 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/1271 ,  A61K9/5078 ,  A61K31/192 ,  A61K31/465 ,  A61K31/506 ,  A61K31/513 ,  A61K31/704 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K33/24 ,  A61K38/00 ,  A61K38/17 ,  A61K38/45 ,  A61K38/47 ,  A61K45/06 ,  A61K47/6923 ,  A61K49/0082 ,  A61K49/0423 ,  B82Y5/00 ,  C07K7/06 ,  C07K2319/00 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2810/40 ,  C12Y204/02036 ,  C12Y302/02022 ,  A61K2300/00

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

Abstract translation: 本发明涉及用于特异性靶向肝细胞和其它癌细胞的原细胞，其包含具有支持的脂质双层的纳米多孔二氧化硅核心; 至少一种促进癌细胞死亡的药物（例如传统的小分子，大分子货物（例如siRNA或蛋白质毒素如蓖麻毒素A链或白喉毒素A链）和/或组蛋白包装的质粒DNA 设置在纳米多孔硅芯内（优选超螺旋以更有效地将DNA包装到原细胞中），其任选地用核定位序列修饰以帮助定位癌细胞核内的原细胞，以及表达参与治疗的肽的能力 （凋亡/细胞死亡）或作为报告物，靶向肽靶向待治疗的组织中的癌细胞，使得原细胞与靶细胞的结合是特异性和增强的，并且促进内体逃逸的融合肽 原细胞和包封的DNA。根据本发明的原细胞可用于治疗癌症，特别是包括肝细胞（肝）癌症 选择性结合肝细胞组织或在癌症诊断中起作用的新型结合肽（c-MET肽），包括癌症治疗和药物发现。